Electronic Patient Reported Outcome (ePRO)

Patients,patient-reported outcomes,study,symptoms,platform,electronic patient-reported outcome,care,measures,cancer,devices,review,mobile devices,tool.

Implementation,patient-reported outcome measures,practice,clinical practice,setting,patient outcomes,patient populations,health,months,Basch,ePRO systems,routine care.

Previous study,electronic device,systematic review,quality of life,life,ePRO tool,type,depression,ePRO platform,drugs,web-based system.

Health-related quality,clinical outcomes,electronic systems,monitoring with patient,comparison with patient,BMC Health Serv Res,usual care,routine cancer treatment,workflow,Institutional Review Board,Basch E,capture,electronic capture,electronic patient-reported outcomes tool,ePRO implementation,clinical settings,oncology clinical,systems in oncology,Sloan JA,target population,adverse events,eligible patients,agreement between patient,Health Journal,Electronic health record,Primary care providers,patient-centered care,observational study,study sites,patient-reported symptoms,Adverse symptom event,anxiety symptoms,JMIR Cancer,Ethan Basch,life assessments,life expectancy,advanced practice providers,Aaronson NK,Additional file,Critical Path Institute,ePRO vendor,digital divide,Jensen RE,JMIR Mhealth Uhealth,stepped-wedge design,Atherton PJ,inclusion criteria,active treatment,home-ePRO patients,Clinic-ePRO patients,anxiety in patients,health system goals,National Institutes of Health,Department of Health,Family Health Teams,mental health status,care partners,complex care,study sponsor,study nurse,depressive symptoms,patients with breast cancer,Navigating Cancer,ePRO workflows,Design workflows,ePRO workflow design,tools with workflow,handheld device,QC review,month control period,month intervals,month intervention period,”Basch,”,ePRO capture,ePRO data capture,ePRO reporting tools,type of eligibility criteria,arm type,type of intervention model,optimal implementation,degree of depression,depression scale,measure selection strategy,technical platforms,hospital setting,Texas Oncology,Food and Drug Administration,U.S. Food and Drug Administration.